ArticleEndocrinology, diabetes & metabolism2026
Interleukin-6 and Oncostatin M Levels in Patients With Type 1 Diabetes and Its Relationship With Glycemic Indices.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 1 diabetes mellitus (T1DM) is an autoimmune disorder characterised by progressive destruction of pancreatic β-cells, in which inflammatory cytokines such as interleukin-6 (IL-6) and oncostatin M (OSM) play key roles. This study aimed to evaluate serum IL-6 and OSM levels and their relationship with glycemic indices in children with T1DM.
methodsIn this cross-sectional study, 80 children (40 with T1DM and 40 controls) aged 3-18 years were included. Exclusion criteria were congenital or inflammatory disorders and use of anti-inflammatory drugs, corticosteroids, NSAIDs, antibiotics, lipid-lowering agents, hypoglycemic drugs, herbal supplements, multivitamins, or special diets. Serum IL-6, OSM, fasting blood sugar (FBS), and HbA1c were measured. Demographic and clinical data-including age, sex, growth percentiles, BMI percentile, blood pressure, duration of diabetes, and history of diabetic ketoacidosis (DKA)-were recorded. Logistic regression was used to identify predictors of glycemic indices, and ROC curve analysis assessed the diagnostic performance of OSM. Statistical significance was set at p < 0.05.
resultsOut of 80 subjects, the mean age was 10.62 (3.3) years in children with T1DM and 11.25 (3.6) years in controls, with a comparable gender distribution (male: 52.5% vs. 60%). Serum OSM levels were significantly higher in children with T1DM (p < 0.001) and strongly predicted elevated HbA1c (adjusted OR = 3.06; 95% CI: 1.84-5.08) and FBS (adjusted OR = 1.70; 95% CI: 1.31-2.20). ROC analysis demonstrated a robust ability to discriminate T1DM from controls (AUC = 0.94; 95% CI: 0.89-0.99), with a cut-off of OSM > 10.0675, yielding a sensitivity and specificity of 87.5%. IL-6 levels did not differ significantly between groups but were higher in children with a history of DKA.
conclusionOSM may represent a sensitive and specific biomarker for distinguishing children with T1DM from healthy individuals, whereas IL-6 appears more closely related to DKA-associated inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.